Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450156 | 0.90 | AOC3 (0.56) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL8059189 | 0.88 | CYP1A2 (0.68) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL7017296 | 0.84 | BRD4 (0.50) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL5725833 | 0.83 | CYP1A2 (0.56) | CYP1A2PKMCYP3A4ALOX15NFKB1 | |
| SCHEMBL358332 | 0.83 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19PKMCYP3A4 | |
| SCHEMBL18722706 | 0.83 | CYP1A2 (0.56) | CYP1A2PKMCYP3A4ALOX15NFKB1 | |
| SCHEMBL31724652 | 0.83 | CYP1A2 (0.56) | CYP1A2PKMCYP3A4ALOX15NFKB1 | |
| SCHEMBL5724150 | 0.82 | ROCK2 (0.68) | ROCK2ROCK1SRCALDH1A1 | |
| SCHEMBL2749289 | 0.81 | SPR (0.63) | KMT2AMMP1MMP2MMP9ALDH1A1 | |
| SCHEMBL2567513 | 0.81 | HSD17B1 (0.55) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023213728-A1 | SUBSTITUTED ARYL ESTERS OF COUMARIN-3-CARBOXYLIC ACID AND THEIR USE AS HOST CELL PROTEASES INHIBITORS | Université de Liège (BE) | 2023-11-09 | — | — | WO | disclosed |
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-4138824-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | Anovia Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20210353683-A1 | ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR | NISSAN CHEMICAL CORPORATION (JP) | 2021-11-18 | — | — | US | disclosed |
| WO-2021216592-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3851519-A1 | ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR | Nissan Chemical Corporation (JP) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020158840-A1 | ANTI-CANCER AGENT | 日産化学株式会社 | 2020-08-06 | — | — | WO | disclosed |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| EP-3101015-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| CN-101479267-B | Purine derivatives as A2A agonists | NOVARTIS AG | 2012-05-02 | — | — | CN | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| CN-101479267-A | Purine derivatives as A2A agonists | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| CN-101472925-A | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-4131751-A | PHENYLENE, PLANT GROWTH REGULATORS | BASF AKTIENGESELLSCHAFT (DE) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | CYP1A2 423/4885CYP2D6 710/4885CYP2C9 612/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | CYP1A2 479/4885CYP2D6 263/4885CYP2C9 190/4885 |
| US-20210353683-A1 | ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR | HGF, HDGF, FGF2 | CYP1A2 4831/4885CYP2D6 4876/4885CYP2C9 4885/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | CYP1A2 301/4885CYP2D6 503/4885CYP2C9 366/4885 |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | TRPA1, TRPV1, TRPV2 | CYP1A2 758/4885CYP2D6 774/4885CYP2C9 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.